1 Definitions of Sarcopenia
2 Epidemiology of Muscle Mass Loss with Age
3 The Role of Mitochondria in Muscle Function
4 Motor unit remodelling
5 Nutrition, Protein Turnover and Muscle
6 Screening for Sarcopenia
7 Adverse Outcomes and Functional Consequences of Sarcopenia
8 A Lifecourse Approach to Sarcopenia
9 Acute Sarcopenia
10 Sarcopenia, Frailty and Intrinsic Capacity
12 Sarcopenic Obesity
13 Sarcopenia and Cognition
14 Sarcopenia and Other Chronic Organ Diseases
15 Imaging of Skeletal Muscle
16 Measurements of Muscle Mass, Equations and Cut-off Points
17 Deuterated creatine dilution to assess muscle mass (D3Cr muscle mass) in humans: methods, early results and future directions
18 Measurement of Muscle Strength and Power
19 Measurements of Physical Performance
20 Biomarkers for Physical Frailty and Sarcopenia: a "Two-Body Problem"
21 Quality of Life and Sarcopenia
22 Exercise Interventions to Prevent and Improve Sarcopenia
23 Nutritional Approaches to Treat Sarcopenia
24 Beta-hydroxy-beta-methylbutyrate (HMB) and Sarcopenia
25 The Future of Drug Treatments
26 Sarcopenia: Is It Preventable?
27 Financial Impact of Sarcopenia
28 Sarcopenia Management For Clinicians
An in-depth examination of sarcopenia's underexplored yet widespread impact within the field of gerontology
Sarcopenia is common in older men and women, and yet awareness of its clinical relevance is still relatively low. Only formally included in the International Classification of Diseases in 2016, the condition may impact societies with serious health-related and financial consequences unless consistent, effective methods of identification and management are adopted.
This second edition of Sarcopenia provides geriatricians and other healthcare professionals with a revised and expanded examination of this understudied and underdiagnosed condition. Edited by two leading authorities on the subject, it covers the epidemiology and diagnosis of sarcopenia, as well as treatment options and possible prevention strategies. Eight newly written chapters build upon existing knowledge with fresh data on topics including sarcopenia's biomarkers and its impact on the healthcare economy. This important text:
- Defines sarcopenia and explains its clinical relevance
- Covers all recent scientific evidence
- Outlines treatment options
- Considers prevention strategies
- Discusses sarcopenia as a public health priority
- Features eight new chapters covering topics such as sarcopenia's clinical management, its biomarkers, and its financial impact
Containing vital information for clinicians and other professionals working in geriatric care, nursing homes, nutrition, cancer, endocrinology, surgery, sports medicine and many other specialties, Sarcopenia, second edition, is a groundbreaking and essential new resource.
Alfonso J. Cruz-Jentoft, MD, Professor, Geriatrics, Universidad Europea de Madrid, and Director of Geriatric Medicine, Hospital Universitario Ramon y Cajal (IRYCIS), Madrid, Spain.
John E. Morley, MD, Professor, Geriatrics, St Louis University Medical School, St Louis, MO, USA.